(S1 (S (S (NP (NP (JJ Granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (CC and) (NP (NN interleukin-3))) (VP (VBP enhance) (NP (NP (NP (DT the) (NN incorporation)) (PP (IN of) (NP (NN cytosine) (NN arabinoside))) (PP (IN into) (NP (NP (DT the) (NN DNA)) (PP (IN of) (NP (JJ leukemic) (NNS blasts)))))) (CC and) (NP (NP (DT the) (JJ cytotoxic) (NN effect)) (PP (IN on) (NP (NP (JJ clonogenic) (NNS cells)) (PP (IN from) (NP (NP (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ myeloid) (NN leukemia))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP (NP (DT the) (NNS effects)) (PP (PP (IN of) (NP (NP (DT the) (JJ 48-hour) (NN administration)) (PP (IN of) (NP (NP (NP (NP (NP (NP (JJ granulocyte-macrophage) (JJ colony-stimulating) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN GM-CSF)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN U/mL)) (-RRB- -RRB-))) (CC or) (NP (NN interleukin-3))) (PRN (-LRB- -LRB-) (NP (NN IL-3)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (NP (CD 100) (NN U/mL)) (-RRB- -RRB-)))) (PP (IN on) (NP (NP (DT the) (JJ proliferative) (NN activity)) (PP (IN of) (NP (JJ leukemic) (NNS cells))))))) (CC and) (PP (IN on) (NP (NP (NP (DT the) (JJ intracellular) (NN metabolism)) (CC and) (NP (JJ cytotoxic) (NN efficacy))) (PP (IN of) (NP (NP (DT a) (JJ subsequent) (NN 12-hour) (NN application)) (PP (IN of) (NP (NP (NN cytosine) (NN arabinoside)) (PRN (-LRB- -LRB-) (NP (NN ara-C)) (-RRB- -RRB-)))) (PP (IN at) (NP (NP (NNS doses)) (PP (IN of) (NP (QP (CD 0.1) (, ,) (CD 1.0) (, ,) (CD 10.0) (, ,) (CC and) (CD 100.0)) (NN mumol/L))))))))))) (VP (VBD were) (VP (VBN evaluated) (PP (IN on) (NP (NP (NN bone) (NN marrow) (NNS cells)) (PP (IN from) (NP (NP (CD 17) (NNS patients)) (PP (IN with) (NP (JJ acute) (JJ myeloid) (NN leukemia)))))))))) (. .)))
(S1 (S (S (PP (IN After) (NP (NP (NN GM-CSF)) (CC or) (NP (NN IL-3)))) (, ,) (NP (NP (DT a) (CD 1.2-) (TO to) (JJ 2.4-fold) (NN increase)) (PP (IN in) (NP (NN S-phase) (NNS cells)))) (VP (VBD was) (VP (VBN observed) (PP (IN in) (NP (NP (NP (CD nine)) (PP (IN of) (NP (CD 14) (NN GM-CSF)))) (CC and) (NP (NP (CD seven)) (PP (IN of) (NP (CD 11) (NN IL-3) (NNS cases))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN 3H-Cytosine) (NN arabinoside)) (NN incorporation)) (PP (IN into) (NP (DT the) (NN DNA)))) (VP (VBD was) (VP (VBN enhanced) (PP (JJ 1.33-) (TO to) (NP (NP (JJ 18.3-fold)) (PP (IN over) (NP (JJ respective) (NNS controls))))) (PP (IN in) (NP (QP (CD 14) (IN of) (CD 17)) (NNS patients)))))) (. .)))
(S1 (S (S (SBAR (IN While) (S (PP (IN in) (NP (NP (NN control) (NNS specimens)) (VP (VBP are) (NP (NN ara-C))))) (NP (NP (JJ dose-dependent) (NN increase)) (PP (IN in) (NP (NN 3H-ara-C) (NN uptake)))) (VP (VBD was) (VP (VBN accompanied) (PP (IN by) (NP (NP (DT a) (JJ corresponding) (NN rise)) (PP (IN in) (NP (JJ intracellular) (JJ ara-C-5') (NN triphosphate) (-LRB- -LRB-) (NN ara-CTP) (-RRB- -RRB-) (NNS levels))))))))) (, ,) (NP (NN ara-CTP) (NNS concentrations)) (VP (VBD were) (RB not) (VP (VBN increased) (PP (IN after) (NP (NP (NP (NN GM-CSF)) (CC or) (NP (NN IL-3))) (NN exposure)))) (, ,) (S (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJR higher) (NN ara-C)) (PP (TO to) (NP (NP (NN ara-CTP) (NN ratio)) (PP (IN over) (NP (NNS controls))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN finding)) (VP (MD may) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (NP (NP (DT a) (JJ stimulatory) (NN effect)) (PP (IN of) (NP (NP (NN GM-CSF)) (CC and) (NP (NN IL-3)))) (PP (IN on) (NP (NN ara-C) (VBG phosphorylating) (NNS enzymes)))) (CC and) (NP (NP (DT a) (ADJP (RBR more) (JJ rapid)) (NN incorporation)) (PP (IN of) (NP (NN ara-CTP))) (PP (IN into) (NP (NP (DT the) (NN DNA)) (PP (IN of) (NP (JJ leukemic) (NNS blasts)))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS effects)) (VP (VBN translated) (PP (IN into) (NP (NP (DT a) (ADJP (CD 2.2-) (TO to) (JJ 229.0-fold)) (NN increase)) (PP (IN in) (NP (NP (DT the) (JJ cytotoxic) (NN activity)) (PP (IN of) (NP (NN ara-C))) (PP (IN against) (NP (NP (JJ clonogenic) (JJ leukemic) (NNS cells)) (PP (IN after) (NP (NP (NP (NN GM-CSF)) (CC or) (NP (NN IL-3))) (NN pretreatment))))))))))) (. .)))
(S1 (S (ADVP (RB Hence)) (, ,) (NP (NP (NN GM-CSF)) (CC and) (NP (NN IL-3))) (VP (VBP enhance) (NP (NP (DT the) (JJ intracellular) (NN metabolism)) (PP (IN of) (NP (NP (NN ara-C)) (CC and) (NP (NP (PRP$ its) (NN incorporation)) (PP (IN into) (NP (NP (DT the) (NN DNA)) (PP (IN of) (NP (NP (JJ leukemic) (NNS cells)) (VP (VBG leading) (PP (TO to) (NP (NP (DT a) (JJR higher) (JJ antileukemic) (NN activity)) (PP (IN of) (NP (NN ara-C))) (PP (IN on) (NP (NP (JJ clonogenic) (JJ leukemic) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN CFU-L)) (-RRB- -RRB-)))))))))))))))) (. .)))
